Mesalamine is indicated for the treatment of mild-moderately active ulcerative colitis (UC) and is often started in moderate-severe disease once remission is achieved with corticosteroids. To determine whether pediatric patients presenting with moderate-severely active UC can successfully be put into remission with mesalamine monotherapy. A retrospective chart review of all pediatric patients with non-fulminate UC managed through induction at a regional pediatric IBD center. Induction was defined as resolution of rectal bleeding. Presentation was classified as mild, moderate or severe using ACG guidelines and physician global assessment (PGA). Clinical, laboratory and endoscopic findings were recorded for patients induced only with mesalamine (MES) and those given steroids (STER). A total of 73 pediatric UC patients were studied. 47 (64.4%) achieved remission with MES alone (average age = 10.03 years; range 1.5—15.5 years; 24 male) compared to 26 given STER (average age = 11.8 years; range 2.5—17.5 years; 14 female). Mean MES dose was 53.3mg/kg/day (range 22-108mg/kg/day). Of the total 73 patients, 53% had an initial PGA of moderate or severe: 18 MES (24.1%) v. 21 (28.8%) STER p = ns. Pancolitis was present in 65% of all patients: MES 25 (35.2%) v. 22 STER (30.1%) p = ns. Mean sedimentation rate was higher in STER (34.2; range 6-90) than MES (14.6; range 1-51) p < 0.05. Hemoglobin at presentation < 10.0 g/dl was seen in 4 (8.5%) MES v. 7 (27%) STER p =0.08. 1. More than one-half of patients with pediatric ulcerative colitis present with moderate-severe disease. 2. Mesalamine monotherapy can be considered for steroid-free induction in the majority of newly diagnosed pediatric UC patients including those who present with moderate-severe disease. 3. The presence of anemia, elevated sedimentation rate and pancolitis may have influenced the use of steroids more than clinical characteristics or PGA. 4. Large, prospective studies are needed to validate these findings. Partially supported by an unrestricted research grant from Procter and Gamble Pharmaceuticals, Cincinnati, Ohio